Supernus Pharmaceuticals has acquired Sage Therapeutics, strengthening its neuropsychiatry product portfolio.

A new report compiles the latest data and insight on scaling cell and gene therapy (CGT) effectively to improve patient access.

BeOne Medicines' investigational Bruton's tyrosine kinase (BTK) degrader, BGB-16673, has received priority medicines (PRIME) designation.

Major pharma manufacturers have a 29 September deadline to adjust their drug prices relative to other developed countries.

Biotechs investigate mitochondria-targeting drugs to claim a share in the weight loss drug market dominated by GLP-1RAs.

Sanofi expanded the sales reach of the drug with approvals in the lucrative chronic obstructive pulmonary disease (COPD) market. Dupixent’s success pushed Sanofi’s total net sales to €9.9bn, up 10% at ...

Director-general for WHO says leaders want self-reliance, with tobacco and alcohol tax rises on the cards to boost domestic revenue.

We spoke to BBG Advanced Therapies COO Adrienne Mendoza to learn how one company is tackling the challenges of cell therapies.